Phase 2 Oesophageal Cancer Trial, Recruiting NCT06435286 Sponsor: Baylor College of Medicine Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06435286
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are attending a routine screening procedure using a special dye (called Lugol's solution) to check for a type of cancer called squamous cell neoplasia in the esophagus (food pipe).
  • People who have a history of head or neck squamous cell cancer, or who have risk factors such as heavy smoking, heavy alcohol use, certain dietary or geographic risk factors, or a previous diagnosis of abnormal cells (dysplasia).
  • People who are older than 18 years of age.
  • People of any sex or gender.
  • People who are willing and able to give their informed consent to take part.

Who may not be able to join:

  • People who have a known allergy or have had a previous reaction to a fluorescent dye called proflavine hemisulfate.
  • People who are unable to give informed consent.
  • People who have a known advanced squamous cell cancer in the lower part of the esophagus, or an abnormal or suspected cancerous lesion in the esophagus that is 2 cm or larger in size and cannot be treated with an endoscopic (camera-based) procedure.
  • People who are pregnant or breastfeeding.
  • People whose blood does not clot properly, based on specific blood test results (confirm with trial site).
  • People who are unable to safely undergo a sedated upper endoscopy (a camera examination of the food pipe under sedation) due to heart or lung instability or other serious health conditions.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mimi C Tan, MD, MPH, Baylor College of Medicine

Phone: 7137980950

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
17 February 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇧🇷 Brazil 🇺🇸 United States

Primary endpoints

Clinical Impact; Performance Characteristics; Procedure Efficiency; Clinician Confidence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov